In addition to these results, we demonstrated that STC2 expression serves as a potential predictive marker for chemotherapy response in both ER-positive and ER-negative grade II breast cancer patients, but with different outcomes: In grade II ER-positive patients, higher STC2 expression correlates with better chemotherapy response. This evidence concerns the gene STC2 and breast carcinoma.